What should be the optimal levels of blood pressure: Does the J-curve phenomenon really exist?

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 12, 2011, Pages 1835-1844

  Banach, MacIej ^a   Michalska, Marta ^a   Kjeldsen, Sverre E ^b   Małyszko, Jolanta ^c   Mikhailidis, Dimitri P ^d   Rysz, Jacek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Blood pressure; Diabetes; Hypertension; Hypotensive therapy; J curve

Indexed keywords

AMLODIPINE; ATENOLOL; ATORVASTATIN; BISOPROLOL; CLONIDINE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NIFEDIPINE; PRAVASTATIN; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

ADVERSE OUTCOME; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); COMORBIDITY; CORONARY ARTERY DISEASE; DEATH; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; J CURVE; OBSERVATIONAL STUDY; PATIENT SAFETY; PATIENT SELECTION; PLOTS AND CURVES; PRACTICE GUIDELINE; PROGNOSIS; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STROKE; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; THEORY;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; HUMANS; HYPERTENSION; HYPOTENSION; PRACTICE GUIDELINES AS TOPIC; REFERENCE VALUES; RISK FACTORS;

EID: 79960462153     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.579106     Document Type: Review

References (57)

1. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;12:2121-58
2. Bielecka-Dabrowa A, Aronow WS, Rysz J, Banach M. Current place of beta-blockers in the treatment of hypertension. Curr Vasc Pharmacol 2010;8:733-41
3. Banach M, Barylski M, Rysz J. What should be the optimal levels of blood pressure? J-curve phenomenon. The scene after ACCORD BP publication. Evid Based Cardiol 2010;1:113-20
4. Banach M, Kjeldsen SE, Narkiewicz K. Editorial. Controversies in hypertension treatment. Curr Vasc Pharmacol 2010;8:731-2
5. Yusuf S, Diener HC, Sacco RL, et al. PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008;359:1225-37
6. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174-83
7. Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006;144:884-93 (Pubitemid 46768128)
8. Sleight P, Redon J, Verdecchia P, et al. ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the ongoing telmisartan alone and in combination with ramipril global endpoint trial study. J Hypertens 2009;27:1360-9
9. Ramezani MA, Dastanpour M, Eshaghi SR, et al. Determinants of awareness, treatment and control of hypertension in Isfahan, Central Iran. Arch Med Sci 2009;5:523-30
10. Stewart IM. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet 1979;1:861-5
11. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet 1987;1(8533):581-4
12. D'Agostino RB, Belanger AJ, Kannel WB, Cruickshank JM. Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham Study. BMJ 1991;303:385-9
13. Hansson L; for the BBB Study Group. The BBB Study: the effect of intensified antihypertensive treatment on the level of blood pressure, side effects, morbidity and mortality in "well-treated" hypertensive patients. Blood Press 1994;3:248-54 (Pubitemid 24257773)
14. The HOT Study Group. The Hypertension Optimal Treatment (HOT) Study-A prospective study of the optimal therapeutic goal and the value of low-dose aspirine in antihypertensive treatment. Blood Press 1993;2:113-19
15. Vokó Z, Bots ML, Hofman A, et al. J-shaped relation between blood pressure and stroke in treated hypertensives. Hypertension 1999;34:1181-15
16. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in The Elderly Program. JAMA 1991;265:3255-64
17. Cruickshank JM. Antihypertensive treatment and the J-curve. Cardiovasc Drugs Ther 2000;14:373-9 (Pubitemid 30663719)
18. Cruickshank JM. Hypertension optimal treatment (HOT) trial. Lancet 1998;352:573-4
19. Zanchetti A, Hansson L, Clement D, et al. HOT Study Group. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? J Hypertens 2003;21:797-804 (Pubitemid 36549676)
20. Hedner T, Oparil S, Narkiewicz K, Kjeldsen SE. The J-curve phenomenon revisited. Blood Press 2009;18:168-70
21. Kjeldsen SE, Kolloch RE, Leonetti G, et al. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. J Hypertens 2000;18:629-42 (Pubitemid 30303495)
22. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al.; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16 (Pubitemid 37509488)
23. Pastor-Barriuso R, Banegas JR, Damian J, et al. Systolic blood pressure, diastolic blood pressure, and pulse pressure: an evaluation of their joint effect on mortality. Ann Intern Med 2003;139:731-9
24. Marschner IC, Simes RJ, Keech A. Biases in the identification of risk factor thresholds and J-curves. Am J Epidemiol 2007;166:824-31 (Pubitemid 47428899)
25. Messerli FH, Panjrath GS. The J-curve between blood pressure and coronary artery disease or essential hypertension? Exactly how essential? J Am Coll Cardiol 2009;54:1827-34
26. Williams B. Hypertension and the "J-curve". J Am Coll Cardiol 2009;54:1835-6
27. Williams B, Lindholm LH, Sever P. Systolic pressure is all that matters. Lancet 2008;371:2219-21
28. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical appraisal. J Hypertens 2009;27:923-34
29. Grassi G, Quarti-Trevano F, Dell'oro R, Mancia G. The "J Curve" problem revisited: old and new findings. Curr Hypertens Rep 2010;12:290-5
30. Verdecchia P, Angeli F, Cavallini C, et al. The optimal blood pressure target for patients with coronary artery disease. Curr Cardiol Rep 2010;12:302-6
31. Fagard RH, Staessen JA, Thijs L, et al. On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Intern Med 2007;167:1884-91 (Pubitemid 47481484)
32. Staessen JA, Thijisq L, Fagard R, et al. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 2004;22:847-57 (Pubitemid 38543578)
33. Julius S, Kjeldsen SE, Weber M, et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31 (Pubitemid 38781102)
34. Bangalore S, Messerli FH. Wun Ch, Zuckerman AL, DeMicco D, Kostis JB, LaRosa JC. J-Curve revisited: an analysis of the treating to new targets (TNT) Trial. J Am Coll Cardiol 2009;53:A217
35. Khush KK, Waters DD, Bittner V, et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the treating to new targets (TNT) study. Circulation 2007;115:576-83 (Pubitemid 46226167)
36. Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004;364:849-57
37. Mancia G, De Backer G, Dominiczak A, et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87 (Pubitemid 46924065)
38. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-72 (Pubitemid 37430158)
39. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010;304:61-18
40. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-85
41. Gerstein HC, Miller ME, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
42. Berl T, Hunsicker LG, Lewis JB, et al. Collaborative Study Group. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005;16:2170-9 (Pubitemid 41716450)
43. Nilsson PM. ACCORD and risk-factor control in type 2 diabetes. N Engl J Med 2010;362:1628-30
44. Cooper-DeHoff RM, Egelund EF, Pepine CJ. Blood pressure lowering in patients with diabetes-one level might not fit all. Nat Rev Cardiol 2011;8:42-9
45. Okin PM, Hille DA, Kjeldsen SE, et al. Lower achieved systolic pressure (a‰ 130 mm Hg) is not associated with improved outcomes in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Circulation 2010;122:A9064
46. Ogihara T, Saruta T, Rakugi H, et al. Valsartan in Elderly Isolated Systolic Hypertension Study Group. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension 2010;56:196-202
47. Bangalore S, Qin J, Sloan S, et al. PROVE IT-TIMI 22 Trial Investigators. What is the optimal blood pressure in patients after acute coronary syndromes? Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation 2010;122:2142-51
48. SPRINT trial. Clinicaltrials.gov. Available from: http://www. clinicaltrials. gov/ct2/show/NCT01206062
49. Pérgola PE, White CL, Graves JW, et al. SPS3 Investigators. Reliability and validity of blood pressure measurement in the Secondary Prevention of Small Subcortical Strokes study. Blood Press Monit 2007;12:1-8
50. Verdecchia P, Staessen JA, Angeli F, et al. Cardio-Sis investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009;374:525-33
51. Arguedas JA. Blood pressure targets: are clinical guidelines wrong? Curr Opin Cardiol 2010;25:350-4
52. Kannel WB, Wilson PW, Nam BH, et al. A likely explanation for the J-curve of blood pressure cardiovascular risk. Am J Cardiol 2004;94:380-4 (Pubitemid 38962714)
53. Sethi A, Arora RR. Ambulatory blood pressure as a predictor of cardiovascular risk. Arch Med Sci 2009;5:3-9
54. Zanchetti A, Mancia G, Black HR, et al. Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J Hypertens 2009;27:673-9
55. Stepien M, Banach M, Jankowski P, Rysz J. Clinical implications of non-invasive measurement of central aortic blood pressure. Curr Vasc Pharmacol 2010;8:747-52
56. Lee TT, Chen J, Cohen DJ, Tsao L. The association between blood pressure and mortality in patients with heart failure. Am Heart J 2006;151:76-83 (Pubitemid 41815334)
57. Desai RV, Banach M, Ahmed MI, et al. Impact of baseline systolic blood pressure on long-term outcomes in patients with advanced chronic systolic heart failure (insights from the BEST trial). Am J Cardiol 2010;106:221-7